The second time may be a charm for Medivation in downtown San Francisco.
Nearly two years ago the San Francisco biotech terminated a 63,817-square-foot lease at 345 Spear St. following a disappointing Phase III trial for Dimebon, the Alzheimer’s drug the company was developing with Pfizer. Now Medivation has a new promising drug — this one a late-stage cancer drug — and a big new lease to go along with it.
No comments:
Post a Comment